{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-105027","form_type":"8-K","ticker":"GPCR","cik":"0001888886","company_name":"Structure Therapeutics Inc.","filed_at":"2023-09-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.000271+00:00","generated_at":"2026-06-10T07:10:59.446552+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Structure Therapeutics GSBR-1290 Phase 1b shows 4.9% weight loss but Phase 2a obesity data delayed to H1 2024","bullets":["Phase 1b MAD: placebo-adjusted weight loss up to 4.9% at day 28; no severe AEs or discontinuations.","Phase 2a obesity cohort data collection omission: 24 of 40 patients missing week 12 weight; new enrollment; topline now H1 2024.","Phase 2a type 2 diabetes cohort topline still on track for latter half Q4 2023.","Phase 2b studies (T2D ~500 pts, obesity ~275 pts) planned for 2024; formulation bridging study to tablets underway.","GSBR-1290 generally well-tolerated; most AEs mild GI events; no clinically meaningful liver function changes."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-105027","json":"https://secwatch.observer/filing/0001104659-23-105027.json","markdown":"https://secwatch.observer/filing/0001104659-23-105027.md","text":"https://secwatch.observer/filing/0001104659-23-105027.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1888886/000110465923105027/0001104659-23-105027-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1888886/000110465923105027/tm2327162d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T07:10:59.446552+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}